Senators urge against unique biosimilar names

A bipartisan group of U.S. senators said FDA should not require biosimilars and reference biologics to have distinct international non-proprietary names (INNs), according to a Amgen Inc. (NASDAQ:AMGN) said "distinguishable product names help facilitate accurate attribution of adverse events and manufacturer accountability." ...